Companion Diagnostics Play a Confusing Role with PD-1 Inhibitors

  There are now three approved drugs that target PD-1 either directly or indirectly, and more are under development.While these drugs all seek to inhibit PD-1’s immune suppressive activity, they are quite different in the ways that companion diagnostic tests play...

Metabolic Biomarkers Dominate Companion Diagnostics

We are soon going to release a report describing trends in the development and use of companion diagnostic biomarkers, and a key part of preparing this report was breaking down companion diagnostic biomarkers into relevant groups.  A very clear initial division is...

Oncologists Struggle to Utilize Precision Medicine

  The challenges faced by oncologists in using biomarker-based tests were underlined in a recent article by Dr. Marcus Neubauer in OncLive. In recent posts in this blog I have focused on the challenges of interpreting genomic data, but Dr. Neubauer emphasizes two...